Contact
searchSearch
HMP Global
Login
Quiz

Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC

12/11/2025

Related Content

Videos
Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 1
03/31/2026
Kelly McCann, MD, PhD; Seth Wander MD, PhD; Jason Mouabbi, MD
03/31/2026
Oncology
Videos
Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready?
03/31/2026
Kelly McCann, MD, PhD; Seth Wander MD, PhD; Jason Mouabbi, MD
03/31/2026
Oncology
Videos
Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 2
03/31/2026
Kelly McCann, MD, PhD; Seth Wander MD, PhD; Jason Mouabbi, MD
03/31/2026
Oncology
Videos
Moving Beyond Chemotherapy in Metastatic Triple-Negative Breast Cancer (mTNBC): Are We Clinically Ready? Round 3
03/31/2026
Kelly McCann, MD, PhD; Seth Wander MD, PhD; Jason Mouabbi, MD
03/31/2026
Oncology

Recent News

News
LB-100 Plus Dostarlimab Shows Clinical Promise in Platinum-Resistant Ovarian Clear Cell Carcinoma
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
Longitudinal ctDNA Clearance Predicts Outcomes in Advanced Ovarian Cancer
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
Chemotherapy Followed by Letrozole Maintains Advantage Over Letrozole Alone in Low-Grade Serous Carcinoma
04/14/2026
Stephanie Holland
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3...
04/14/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Oncology
News
Gedatolisib-Based Regimens for HR-Positive, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer
04/08/2026
Stephanie Holland
Results from the phase 3 VIKTORIA-1 trial demonstrate that gedatolisib-based regimens significantly improved outcomes for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Results from the phase 3 VIKTORIA-1 trial demonstrate that gedatolisib-based regimens significantly improved outcomes for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Results from the phase 3...
04/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use